About HN Cure Pharma Private Limited
Data last updated:
HN Cure Pharma Private Limited is a private limited company based in Delhi, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 28 August 2018 and has been in existence for over 8 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U51909DL2018PTC337895. Its GSTIN is 07AAECH6290C1ZP (Delhi).
The company has an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors Ankur Varshney and Khushbu Varshney.
Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at Office No. – 302 3rd Floor Plot No. 06 Anupam Plaza – I Local Shopping Complex, Gazipur, Delhi, India – 110096.
As per the financials filed for FY 2024, the company reported a revenue of ₹3 Cr, a growth of 13% compared to the previous year. For the same year it recorded a net profit of ₹33.35 Lakh (net margin 11.1%) and EBITDA of ₹50 Lakh (EBITDA margin 16.7%). Revenue has grown at a compounded annual rate (CAGR) of 42% over three years and 51% over five years.
The company is associated with 1 brand: HN Cure Pharma.
For more details, the company can be reached via its website hncurepharma.com.
Company details
Contact details
HN Cure Pharma Private Limited's registered office is in Delhi, Delhi. Its website is hncurepharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered AddressOffice No. – 302 3rd Floor Plot No. 06 Anupam Plaza – I Local Shopping Complex, Gazipur, Delhi, India – 110096
- IndustryPharma, Drug Formulation & Development
To see the full contact details of HN Cure Pharma Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
HN Cure Pharma operates one associated brand: HN Cure Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Pharmaceutical products manufacturing and distribution across medical sectors such as Cardiology and Neurology. | hncurepharma.com |
Business activity
The main business activity of HN Cure Pharma is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of HN Cure Pharma Private Limited, buy the company report.
Financials of HN Cure Pharma Private Limited
FY 2024 filings availableHN Cure Pharma Private Limited reported revenue of ₹3 Cr (up 13% YoY) for FY 2024.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 51% over five years, including 13% growth in the latest year. EBITDA rose 80% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹50 Lakh | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹33.35 Lakh | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 16.7% | ||||
| Net Profit Margin | 11.1% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of HN Cure Pharma Private Limited, buy the company report.
Board of directors of HN Cure Pharma Private Limited
HN Cure Pharma has 2 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Ankur Varshney | Director | 28 Aug 2018 | 8 Years 1 Months | Current |
| Khushbu Varshney | Director | 28 Aug 2018 | 8 Years 1 Months | Current |
Peer comparison
HN Cure Pharma Private Limited is compared with the 10 companies closest to it by revenue in the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Lycus Pharma Private Limited | ₹3 Cr (FY 2022) | 27.0% | Tiruvalla, Kerala, India | |||
| CLV Fashion Private Limited | ₹3 Cr (FY 2019) | Ghaziabad, Uttar Pradesh, India | ||||
| Goenka Engineering and Industrial Pvt Ltd | ₹3 Cr (FY 2025) | -7.0% | New Delhi, Delhi, India | |||
| Torance Health Care Private Limited | ₹3 Cr (FY 2025) | -11.0% | Ambala Cantt, Haryana, India | |||
| Rejuve Organics Private Limited | ₹3 Cr (FY 2025) | 68.0% | New Delhi, Delhi, India | |||
| HN Cure Pharma Private Limitedthis company | ₹3 Cr (FY 2024) | ₹33.35 Lakh | 11.1% | 13.0% | Delhi, India | |
| Narang Intermediaries Private Limited | ₹3 Cr (FY 2025) | -26.0% | New Delhi, Delhi, India | |||
| NP Ram Krishna Enterprises Private Limited | ₹3 Cr (FY 2024) | 11.0% | Gorakhpur, Uttar Pradesh, India | |||
| Indophin Remedies Private Limited | ₹3 Cr (FY 2025) | -26.0% | Naraingarh, Haryana, India | |||
| Sai Astita Gold Private Limited | ₹3 Cr (FY 2024) | 26.0% | Bhubaneswar, Odisha, India | |||
| Medleymed Healthcare Solutions Private Limited | ₹3 Cr (FY 2024) | -43.0% | Hyderabad, Telangana, India |
To see the full peer comparison of HN Cure Pharma Private Limited, buy the company report.
Auditor
HN Cure Pharma Private Limited is audited by DEEPESH SHARMA & CO. for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| DEEPESH SHARMA & CO. | FY 2023 | 415903 |
Shareholding
The shareholding of HN Cure Pharma Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of HN Cure Pharma Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving HN Cure Pharma Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for HN Cure Pharma Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
HN Cure Pharma has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 07AAECH6290C1ZP | Delhi | Active | 20 Sep 2018 |
To see the full GST registrations and return filing status of HN Cure Pharma Private Limited, buy the company report.
Recent activity
HN Cure Pharma Private Limited has 2 board changes on record since 2018: 2 appointments. The latest: Ankur Varshney was appointed as Director on 28 Aug 2018.
Frequently asked questions
HN Cure Pharma is an active private limited company based in Delhi, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 28 August 2018 (8+ years old) and is registered under CIN U51909DL2018PTC337895.
HN Cure Pharma has 2 current directors:
- Ankur Varshney - Director
- Khushbu Varshney - Director
The latest financial statements of HN Cure Pharma on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2024. Year-wise statements from FY 2019 are in the company report.
The GSTIN of HN Cure Pharma is 07AAECH6290C1ZP, registered in Delhi.
The CIN (Corporate Identification Number) of HN Cure Pharma is U51909DL2018PTC337895. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
HN Cure Pharma was incorporated on 28 August 2018, making it 8+ years old. It is registered with the Registrar of Companies, Delhi.
The peers of HN Cure Pharma by revenue are Lycus Pharma Private Limited, CLV Fashion Private Limited, Goenka Engineering and Industrial Pvt Ltd, Torance Health Care Private Limited, Rejuve Organics Private Limited and 5 more, all in the same principal business activity (wholesale trading).
Ankur Varshney was appointed as Director on 28 Aug 2018. Khushbu Varshney was appointed as Director on 28 Aug 2018.
HN Cure Pharma can be reached through the website hncurepharma.com. Its registered office is in Delhi, India.
The registered office of HN Cure Pharma is at Office No. – 302 3rd Floor Plot No. 06 Anupam Plaza – I Local Shopping Complex, Gazipur, Delhi, India – 110096.
HN Cure Pharma operates in the pharma industry, in the drug formulation and development segment.